Rosetta Posts Lower Q1 Losses on Decreased Costs | GenomeWeb

Rosetta Genomics last week reported a drop in its first-quarter loss as it trimmed business costs and research and development spending.

For the three-month period ended March 30, the company's net loss fell to $1.7 million, or $0.07 per share, from a year-ago loss of $3.7 million, or $0.23 per share.

R&D expenses in the quarter shrank to $1 million from $1.6 million in the same period a year earlier, while marketing and business costs dropped to $625,000 from $1.2 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.